All In Biotech

Drug Trial Radar · NCT03275103

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

355

Actual

Start

Sep 19, 2017

Primary completion

Jan 7, 2026

Study completion Jan 7, 2026

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

  • TocilizumabDrug

    Tocilizumab will be administered as premedication during Cycle 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 8 years
  2. Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 8 years
  3. Arms E and J Only: Incidence and Severity of Cytokine-release Syndrome (CRS) Following Tocilizumab Premedication Followed by Treatment with CevostamabTime frame: Up to approximately 8 years

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Hospital - Arizona

    Scottsdale, Arizona

  • City of Hope

    Duarte, California

  • University of Colorado Denver

    Aurora, Colorado

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Peter MacCallum Cancer Center

    East Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • University of Calgary Cumming School of Medicine

    Calgary, Alberta, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain

  • Clinica Universidad de Navarra

    Pamplona/iruña, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.